Senior lawyer and former board member of Tata Trusts, Darius Khambata, has defended his earlier criticism of N Chandrasekaran’s re-appointment as Tata Sons Chairman and has called out fellow trustees Vijay Singh and Venu Srinivasan for doing a volte-face on the issue of listing.
Earlier this month, Khambata said Tata Sons board’s decision, on September 17, to reappoint Chandrasekaran had sullied the company’s reputation. Stung by the criticism, Singh and Srinivasan challenged Khambata on several issues, including Chandrasekaran’s re-appointment, the proposed listing of Tata Sons, and also accused him of orchestrating changes in board of the Sir Dorabji Tata Trust.
Now, Khambata has hit back against the duo.
“There is no contradiction in my position on Chandra’s third term. The performance figures he presented to us in July 2025 were very impressive and led me to vote for his reappointment, and I abided by that resolution throughout. His overall performance has been excellent, and his contribution over the years to the Group has been of a very high order: my letter to him said so. My letter of November 2 was not about Chandra’s performance but about how the Tata Sons board acted on September 17,” Khambata wrote on Tuesday.
Chandrasekaran had announced in August that he would not seek re-appointment as chairman. After this, Tata Trusts decided to constitute a selection committee to appoint a new Chairman.
Khambata has questioned Srinivasan on whether he drew the attention of the Tata Sons nomination and remuneration committee (NRC) to Tata Trusts’ decision to constitute a selection committee. “Your ‘complete’ sequence of events leaves out these crucial facts,” Khambata remarked.
Srinivasan is also a member of the Tata Sons board and had voted in favour of reappointing Chandrasekaran. Along with Singh, he has also complained to the Charity Commissioner of Maharashtra regarding misgovernance in Tata Trusts. The two have also taken a stance in favour of listing Tata Sons shares, which pits them against Tata Trusts Chairman Noel Tata.
“You choose to miss the wood for the trees on listing. My grievance is why you repeatedly voted to oppose listing but suddenly did a volte-face in April 2026 (not a betrayal, as you wrongly characterise my allegation). The merits or demerits of listing are a debate that should be had at a Trust meeting, not in correspondence. That is precisely the debate you did not initiate – the correct course rather than going to the media. As an aside, your example of Novo Nordisk is misconceived: the structure of Novo Nordisk is similar to that of Tata Sons today and is a strong argument against listing,” Khambata said.
He also denied allegations that he strategised to oust Srinivasan and Singh from the board of Tata Sons. “Had I been acting as part of any strategy, I would not have voted to reappoint Venu both in October and November 2025, when my one vote could have easily blocked his reappointment,” he said.
Published on November 17, 2026




